Scott Bradley

Scott Bradley, VP of AI and Innovation at Novartis, shares insights on how AI is revolutionizing early drug development. He discusses the shift from intuition-based decisions to data-driven strategies in the pharmaceutical industry. The conversation highlights the advancements in protein design and the emergence of niche therapies targeting smaller patient populations. Bradley emphasizes how predictive analytics are reshaping timelines and decision-making, pushing pharma towards a tech-centric model for innovation.